drugset / Trial / NCT02051764

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

NCT02051764

Phase 2 Terminated 44 enrolled Avid Radiopharmaceuticals
NaSingle-groupOpen-labelDiagnostic

Summary

This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.

Timeline

Start
2014-05
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir F18 Diagnostic / imaging agent 370 mbq Intravenous
Background florbetapir F 18 Diagnostic / imaging agent 370 mbq Intravenous

Indications